The U.S. Food and Drug Administration (FDA) has granted approval for ANDA 087274, submitted by Watson Labs. The application covers two injectable hydroxyzine hydrochloride products:
* Product 001 – 25 mg/mL strength, injectable dosage form, route: injection.
* Product 002 – 50 mg/mL strength, injectable dosage form, route: injection.
Both products are marked as discontinued in the FDA’s database. The original submission (type: ORIG, submission number 1) received an approved status (AP) on July 28, 1981.
These approvals add to the record of hydroxyzine hydrochloride injectable offerings, though the discontinued status indicates they are no longer marketed.
法规动态2026年8月25日•1 分钟阅读
FDA Approves ANDA087274 for Hydroxyzine Injectable – Watson Labs
FDA approved ANDA087274 for two hydroxyzine hydrochloride injectable products from Watson Labs; both are now listed as discontinued.
由 PharmaCountry 团队整理 · 来源： FDA.gov
评分
(0)
(0)
(0)
(0)
(0)
留下您的评分